TrialThe lancet. HIV2022

Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis.

David Macleod et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.